Keyword: Mosquirix

Here is some other vaccine news of note for the week.

PATH, Walter Reed and GSK have partnered to determine whether tweaking the regimen of Mosquirix could lead to better malaria protection.

Malaria parasites can shuffle genes to create different strains, a phenomenon that could put the efficacy of Glaxo’s vaccine Mosquirix, among others, into question.

WHO plans real-world pilot studies of GlaxoSmithKline’s malaria jab Mosquirix in three African countries.

Sanaria’s malaria vaccine posted more positive clinical data, but a notable gap compared with results from U.S. studies calls for regimen improvements.

Sanaria's malaria vaccine is one step closer to challenging GlaxoSmithKline's Mosquirix, thanks to data from a recent clinical trial.

The WHO said the first-of-a-kind GlaxoSmithKline’s malaria vaccine is ready for local pilots with $15 million in new funding from a global financing group.

While GlaxoSmithKline’s first-of-a-kind malaria vaccine, Mosquirix, is tied up with pilot projects, a competitor may be nearing in Sanaria’s PfSPZ.

Researchers already knew that the protection offered by GlaxoSmithKline’s malaria vaccine--the world’s first--wanes over time. But new data shows it may dwindle to nearly nothing sooner than they expected.

In a study that could provide a needed boost for malaria vaccine research, a team in Australia has blocked P. falciparum parasites from infecting human red blood cells by targeting three proteins found to be necessary for infection.